The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Zolgensma Market At The End Of The 2026–2030 Forecast Period?

Historical growth stemmed from advancements in gene therapy delivery systems, successful clinical outcomes for SMA type 1 treatment, the facilitation of early diagnosis via newborn screening, favorable regulatory frameworks for gene therapies, and the broadening of pediatric neuromuscular care services.

The projected growth during this period can be ascribed to escalating investment in gene therapy pipelines, the expansion of newborn screening initiatives, a surging demand for rare disease treatments that offer a cure, breakthroughs in viral vector manufacturing, and a heightened focus on the long-term economic benefits for health. Significant trends anticipated within this forecast period encompass the increasing acceptance of one-time gene therapies, a greater emphasis on early genetic intervention, the growing deployment of viral vector technologies, the broadening of curative treatment strategies, and an intensified focus on long-term survival outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

What Primary Drivers Are Shaping The Development Of The Zolgensma Market?

The growing occurrence of spinal muscular atrophy is projected to drive the expansion of the zolgensma market in the future. Spinal muscular atrophy (SMA) is a genetic condition marked by the deterioration of spinal cord motor neurons, causing progressive muscle weakness and wasting, mainly impacting infants and young children, and potentially leading to severe physical disabilities and life-threatening issues. This rise in SMA incidence stems from better genetic testing and newborn screening initiatives, allowing for quicker and more precise diagnoses, thereby uncovering more cases that might have previously gone undetected. Zolgensma functions by providing a working copy of the SMN1 gene to individuals with spinal muscular atrophy (SMA), tackling the disease’s root genetic cause and aiding in the restoration of the survival motor neuron (SMN) protein, vital for motor function and muscle strength, eventually enhancing motor abilities and survival in affected infants and young children. For example, as reported by the UK-based health guidance provider Nice organization in August 2025, Spinal muscular atrophy (SMA) is estimated to affect approximately 1 out of every 14,000 births globally, with about 47 babies born with SMA in the UK alone in 2023. Consequently, the rising occurrence of spinal muscular atrophy is fueling the expansion of the zolgensma market.

Zolgensma Market Driver: Rising Prevalence of Rare Diseases Driving Demand for Advanced Gene Therapies

What Segment Types Make Up The Zolgensma Market?

The zolgensma market covered in this report is segmented –

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1, Spinal Muscular Atrophy (SMA) Type 2, Spinal Muscular Atrophy (SMA) Type 3, Pre-symptomatic Spinal Muscular Atrophy (SMA)

2) By Age Group: Pediatric (Infants And Children), Adults

3) By Distribution Channel: Hospitals, Specialty Clinics, Pharmacies

Who Are The Key Players Driving Competition In The Zolgensma Market?

Major companies operating in the zolgensma market are Novartis AG

Read the full zolgensma market report here:

https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

How Does The Zolgensma Market Perform Across Major Global Regions?

North America was the largest region in the zolgensma market in 2025. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Zolgensma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20373&type=smp

Browse Through More Reports Similar to the Global Zolgensma Market 2026, By The Business Research Company

Zinc Chemicals Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-chemicals-global-market-report

Zinc Oxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-oxide-global-market-report

Zinc Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model